Moderna, Inc. (NASDAQ:MRNA - Get Free Report)'s stock price rose 8.8% during trading on Tuesday . The company traded as high as $35.00 and last traded at $35.90. Approximately 3,115,410 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 12,516,600 shares. The stock had previously closed at $32.99.
MRNA has been the topic of several research analyst reports. Wolfe Research initiated coverage on Moderna in a report on Friday, November 15th. They issued an "underperform" rating and a $40.00 price objective on the stock. Barclays downgraded Moderna from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $111.00 to $45.00 in a report on Tuesday. UBS Group cut their price objective on Moderna from $108.00 to $96.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Leerink Partners cut their price objective on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Finally, The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and cut their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $61.58.
Read Our Latest Report on Moderna
The company has a 50 day simple moving average of $38.61 and a 200 day simple moving average of $53.82. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $13.75 billion, a PE ratio of -6.14 and a beta of 1.59.
In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company's stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 2,664 shares of company stock valued at $115,210 in the last ninety days. Insiders own 15.70% of the company's stock.
A number of large investors have recently modified their holdings of the business. Arkadios Wealth Advisors raised its stake in shares of Moderna by 2.2% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company's stock worth $764,000 after buying an additional 243 shares in the last quarter. Knuff & Co LLC raised its stake in shares of Moderna by 5.4% during the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company's stock worth $316,000 after buying an additional 244 shares in the last quarter. Stephens Inc. AR grew its holdings in shares of Moderna by 7.9% in the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company's stock worth $223,000 after acquiring an additional 245 shares during the period. Allworth Financial LP grew its holdings in shares of Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company's stock worth $73,000 after acquiring an additional 281 shares during the period. Finally, Howard Capital Management Inc. grew its holdings in shares of Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after acquiring an additional 297 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.